ASH 2015: As CAR-T Players Vie For 1st Place, Will Efficacy Trump Safety?

Data for chimeric antigen receptor T-cell (CAR-T) therapies from Novartis AG, Kite Pharma Inc. and Juno Therapeutics Inc. have shown similarly impressive efficacy and safety, so the companies are vying for position as the first to market with a CAR-T therapy for hematological malignancies.